The Combined Inhibition of SREBP and mTORC1 Signaling Synergistically Inhibits B‐Cell Lymphoma
Cancer Medicine · 2024-11 · 13 (21)
DOI: 10.1002/cam4.70342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 05.11.2024. Verfasst von Zhenhan Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Mechanistic Target of Rapamycin Complex 1, Signal Transduction, Cell Proliferation, Lymphoma, B-Cell. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, American Cancer Society.
Abstract (Originalsprache)
Background
The sterol regulatory element‐binding protein (SREBP) pathway is essential for maintaining sterol homeostasis during B cell activation and germinal center B cell proliferation. However, its potential as a therapeutic target to treat B‐cell lymphoma remains unclear.
Methods
We examined SREBP protein expression in human B‐cell lymphoma samples using immunohistochemistry. Additionally, we conducted in vitro studies using SREBP signaling inhibitors in combination with rapamycin to assess their effects on cell proliferation and lipid metabolism in B‐cell lymphoma cells.
Results
Our analysis revealed high levels of SREBP2 protein expression in human B‐cell lymphoma samples. Inhibiting SREBP signaling or its downstream target HMG‐CoA reductase (HMGCR) with Fatostatin or Simvastatin effectively suppressed B‐cell lymphoma cell proliferation. However, B‐cell lymphoma cells responded to statin treatment by activating the mTORC1‐pS6 pathway, suggesting a compensatory mechanism to overcome statin‐induced cell cycle arrest. Combining low‐dose statin treatment with the mTOR inhibitor rapamycin produced a synergistic effect, significantly inhibiting B‐cell lymphoma proliferation, cell cycle progression, and lipid raft formation.
Conclusions
These results highlight the potential of a combined therapeutic approach targeting both SREBP and mTORC1 as a novel strategy for treating B‐cell lymphoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, Arizona, USA.
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Indiana University Cooperative Center of Excellence in Hematology (CCEH), Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Wei Luo
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
- American Cancer Society
- Ralph W. and Grace M. Showalter Research Trust Fund
Zitieren
APA
Zhu, Z., Jiang, W., Zhou, J., Maldeney, A. R., Liang, J., Yang, J., & Luo, W. (2024). The Combined Inhibition of SREBP and mTORC1 Signaling Synergistically Inhibits B‐Cell Lymphoma. Cancer Medicine, 13(21). https://doi.org/10.1002/cam4.70342
Vancouver
Zhu Z, Jiang W, Zhou J, Maldeney AR, Liang J, Yang J, et al. The Combined Inhibition of SREBP and mTORC1 Signaling Synergistically Inhibits B‐Cell Lymphoma. Cancer Medicine. 2024;13(21). doi:10.1002/cam4.70342
BibTeX
@article{Zhu2024,
author = {Zhu, Zhenhan and Jiang, Wenxia and Zhou, Jiehao and Maldeney, Alexander Robert and Liang, Jingru and Yang, Jing and Luo, Wei},
title = {The Combined Inhibition of SREBP and mTORC1 Signaling Synergistically Inhibits B‐Cell Lymphoma},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {21},
doi = {10.1002/cam4.70342}
}
EUVIMED